利用结局导向聚类分析识别1型糖尿病风险表型
研究在TrialNet Pathway to Prevention研究的1123例1型糖尿病患者非糖尿病自身抗体阳性亲属中测试结局导向聚类方法,以进展至1型糖尿病时间为结局,识别出6个聚类并归为3个风险组;独立数据集(n=706)验证聚类可识别特征相似个体。
要点
- A组聚类血糖均值AUC中位数9.48 mmol/l,2年无糖尿病生存概率0.42(95%CI 0.34, 0.51)。
- B组聚类IA-2A滴度中位数287 DK单位/ml,2年无糖尿病生存概率0.73(95%CI 0.67, 0.80)。
- C组含4个低风险聚类,2年无糖尿病生存概率范围0.84-0.99。
核心结论
- 人口学、代谢、免疫学和遗传标志物可用于识别有1型糖尿病家族史的自身抗体阳性个体中特征不同、进展风险不同的聚类。
- 结果还揭示人群异质性及变量间复杂交互作用。
研究设计与样本
- 在TrialNet Pathway to Prevention研究的1123例初始非糖尿病自身抗体阳性1型糖尿病亲属中测试结局导向聚类方法。
- 以进展至1型糖尿病时间为结局,模型变量包括人口学特征、遗传、代谢因素和胰岛自身抗体。
- 使用独立数据集糖尿病预防试验1型糖尿病研究(n=706)进行验证。
主要发现
- 分析识别出6个1型糖尿病风险不同的聚类,按聚类层级归为3组。
- A组含1个聚类,血糖均值AUC中位数9.48 mmol/l(IQR 9.16-10.02),2年无糖尿病生存概率0.42(95%CI 0.34, 0.51)。
- B组含1个聚类,IA-2A滴度中位数287 DK单位/ml(IQR 250-319),自身抗体滴度升高,2年无糖尿病生存概率0.73(95%CI 0.67, 0.80)。
- C组含4个较低风险聚类,自身抗体滴度和血糖水平较低,4个聚类2年无糖尿病生存概率范围为0.84-0.99,聚类间血糖、C肽和年龄等特征存在差异。
- 开发了将个体分配至聚类的决策规则,验证数据集确认聚类可识别特征相似个体。
关键数值与推荐
- A组聚类血糖均值AUC中位数9.48 mmol/l(IQR 9.16-10.02),2年无糖尿病生存概率0.42(95%CI 0.34, 0.51)。
- B组聚类IA-2A滴度中位数287 DK单位/ml(IQR 250-319),2年无糖尿病生存概率0.73(95%CI 0.67, 0.80)。
- C组4个较低风险聚类2年无糖尿病生存概率范围为0.84-0.99。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Although statistical models for predicting type 1 diabetes risk have been developed, approaches that reveal the heterogeneity of the at-risk population by identifying clinically meaningful clusters are lacking. We aimed to identify and characterise clusters of islet autoantibody-positive individuals who share similar characteristics and type 1 diabetes risk. METHODS: We tested a novel outcome-guided clustering method in initially non-diabetic autoantibody-positive relatives of individuals with type 1 diabetes, using the TrialNet Pathway to Prevention study data (n=1123). The outcome of the analysis was the time to development of type 1 diabetes, and variables in the model included demographic characteristics, genetics, metabolic factors and islet autoantibodies. An independent dataset (the Diabetes Prevention Trial of Type 1 Diabetes Study) (n=706) was used for validation. RESULTS: The analysis revealed six clusters with varying type 1 diabetes risks, categorised into three groups based on the hierarchy of clusters. Group A comprised one cluster with high glucose levels (median for glucose mean AUC 9.48 mmol/l; IQR 9.16-10.02) and high risk (2-year diabetes-free survival probability 0.42; 95% CI 0.34, 0.51). Group B comprised one cluster with high IA-2A titres (median 287 DK units/ml; IQR 250-319) and elevated autoantibody titres (2-year diabetes-free survival probability 0.73; 95% CI 0.67, 0.80). Group C comprised four lower-risk clusters with lower autoantibody titres and glucose levels (with 2-year diabetes-free survival probability ranging from 0.84-0.99 in the four clusters). Within group C, the clusters exhibit variations in characteristics such as glucose levels, C-peptide levels and age. A decision rule for assigning individuals to clusters was developed. Use of the validation dataset confirmed that the clusters can identify individuals with similar characteristics. CONCLUSIONS/INTERPRETATION: Demographic, metabolic, immunological and genetic markers may be used to identify clusters of distinctive characteristics and different risks of progression to type 1 diabetes among autoantibody-positive individuals with a family history of type 1 diabetes. The results also revealed the heterogeneity in the population and complex interactions between variables.
引用
- You L, Ferrat LA, Oram RA, et al. Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis. Diabetologia. 2024. PMID: 39103721. doi:10.1007/s00125-024-06246-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。